CD40 ligand antagonist dazodalibep in Sjögren’s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Nature Medicine

Topics

Medicine

Cancer Oncology

Immunology

Pathology

Physiology

Show all topics

DOI

10.1038/s41591-024-03009-3

License

CC-BY

Other Formats

PDF